Impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes
about
Resolvins and omega three polyunsaturated fatty acids: Clinical implications in inflammatory diseases and cancerThe resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolutionActivation and resolution of periodontal inflammation and its systemic impact.High ω3-polyunsaturated fatty acids in fat-1 mice prevent streptozotocin-induced Purkinje cell degeneration through BDNF-mediated autophagyRelationship between glycemic control and histochemical myeloperoxidase activity in neutrophils in patients with type 2 diabetesHuman Periodontal Stem Cells Release Specialized Proresolving Mediators and Carry Immunomodulatory and Prohealing Properties Regulated by LipoxinsTherapeutic Targets for Management of Periodontitis and DiabetesInterleukin-1 and estrogen protect against disseminating dentoalveolar infectionsTreating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms.Resolvin E1 Reverses Experimental Periodontitis and Dysbiosis.Neutrophil Resolvin E1 Receptor Expression and Function in Type 2 Diabetes.FOXO1 Regulates Bacteria-Induced Neutrophil Activity.Therapeutic Targets for Management of Periodontitis and Diabetes.Molecular basis for immunohistochemical and inflammatory changes during progression of gingivitis to periodontitis.Paradigm shift - Metabolic transformation of docosahexaenoic and eicosapentaenoic acids to bioactives exemplify the promise of fatty acid drug discovery.ERV1/ChemR23 Signaling Protects Against Atherosclerosis by Modifying Oxidized Low-Density Lipoprotein Uptake and Phagocytosis in Macrophages
P2860
Q26741524-D2FB3E18-F5C9-407A-9409-CB094255319DQ28260186-0E5C84A6-4DE4-44E3-B09E-C96983AA7D1BQ35932966-F6471055-2A84-4C5E-B7AA-E7A4C6D2B0DDQ36209582-2D8F4439-F32F-4AF8-9DD0-9BA5345F70CBQ36417045-78DE9502-C715-47DA-8ABC-19B658AA7F60Q36440765-F6934890-A73A-475C-9384-FB18BC1D1041Q36863273-66CC3D7C-8728-447B-9EBB-DD54EC0346A5Q37736473-7E18A80C-EFC5-4708-9D4A-35AF6A569470Q39088075-C3A377F2-E68D-4995-911D-C72F063C82D0Q39471464-0BD94497-2213-4224-9D75-DBB424BF7ECFQ40403668-E9AA5023-1856-4009-A601-6FA7B23003A4Q41468462-D583E736-E6C3-4824-BF9D-A1592D713FBAQ47121974-93959591-7C63-45D4-8F48-8E490CF9C2BDQ50193589-9A0A6DE3-1648-45AE-843E-45C803F17673Q52369219-5351D8B4-DDBA-4AA2-BD6B-42605885E6F5Q59135574-7586D9EC-4AA6-4E11-BC9E-2232A930B0E7
P2860
Impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes
@ast
Impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes
@en
Impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes
@nl
type
label
Impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes
@ast
Impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes
@en
Impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes
@nl
prefLabel
Impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes
@ast
Impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes
@en
Impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes
@nl
P2093
P2860
P356
P1476
Impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes
@en
P2093
Alpdogan Kantarci
Bruno S Herrera
Hatice Hasturk
Olivia Nguyen
Shevali Kansal
Thomas E Van Dyke
P2860
P304
P356
10.1128/IAI.02444-14
P407
P577
2014-12-08T00:00:00Z